AIDS Activists Slam Biden-Gilead Deal Over HIV Prevention Drug Patents

AIDS activists are criticizing a deal between the Biden administration and Gilead Sciences regarding patents for HIV prevention drugs. They argue the agreement limits access to crucial pre-exposure prophylaxis (PrEP) medications, despite the U.S. government having contributed to the drug's development. This move could hinder wider availability and affordability of life-saving treatment.